SLOAD: a comprehensive database of cancer-specific synthetic lethal interactions for precision cancer therapy via multi-omics analysis

Li Guo¹, Yuyang Dou¹, Daoliang Xia¹, Zibo Yin¹, Yangyang Xiang¹, Lulu Luo², Yuting Zhang¹, Jun Wang¹ and Tingming Liang²,∗

¹Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, China
²Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, No. 1, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, China

© The Author(s) 2022. Published by Oxford University Press.

Abstract

Synthetic lethality has been widely concerned because of its potential role in cancer treatment, which can be harnessed to selectively kill cancer cells via identifying inactive genes in a specific cancer type and further targeting the corresponding synthetic lethal partners. Herein, to obtain cancer-specific synthetic lethal interactions, we aimed to predict genetic interactions via a pan-cancer analysis from multiple molecular levels using random forest and then develop a user-friendly database. First, based on collected public gene pairs with synthetic lethal interactions, candidate gene pairs were analyzed via integrating multi-omics data, mainly including DNA mutation, copy number variation, methylation and mRNA expression data. Then, integrated features were used to predict cancer-specific synthetic lethal interactions using random forest. Finally, SLOAD (http://www.tmliang.cn/SLOAD/) was constructed via integrating these findings, which was a user-friendly database for data searching, browsing, downloading and analyzing. These results can provide candidate cancer-specific synthetic lethal interactions, which will contribute to drug designing in cancer treatment that can promote therapy strategies based on the principle of synthetic lethality.

Database URL: http://www.tmliang.cn/SLOAD/

Introduction

Accumulating evidence has revealed that synthetic lethality (SL) has been an emerging and important therapeutic strategy for cancer treatment by exploiting potential interactions between driving mutations and specific drug targets. A synthetic lethal interaction occurs when the perturbation of two nonessential genes with SL is lethal (1), which can be harnessed to selectively treat cancer via characterizing inactive genes and then targeting the corresponding synthetic lethal partners (2). These genetic interactions between tumor suppressor genes and other genes can simultaneously disrupt both gene functions, which further cause rapid and selective
cell death (3). The strategy of SL provides an opportunity for mutations caused by a loss of function without available targeted therapies. The concept of ‘synthetic lethality’ has been widely concerned in cancer treatment, and treatment of cancer-deficient tumors with PARP inhibitors always selectively kills the cancer cells in some cancers (4–9). Thus, this phenomenon caused by synthetic lethal interactions provides a possibility to develop selective anticancer drugs by targeting a gene whose partner is inactive only in tumor cells (1, 10).

Based on the potential application of SL in cancer treatment, it is quite crucial to obtain a data set containing synthetic lethal interactions with higher confidence that can provide data references for precision cancer therapy. In recent years, many studies attempted to find synthetic lethal interactions, especially potential interactions in some model organisms (11–14) and humans (2, 15–21). According to phylogenetic conservation, some human synthetic lethal interactions have been computationally inferred from yeast (22) and collected via using metabolic models and evolutionary characteristics of metabolic genes (23–25). These predicted interactions provide many references for human genetic interactions, but SL in humans is far more complex than we initially thought. Currently, many candidate interactions have been reported based on diverse approaches or algorithms (26–29), even via integrating multiple molecular levels, and these studies largely contribute to revealing the synthetic lethal interactions and promoting their potential application in cancer precision treatment. However, it is not sufficient to further understand these interactions, particularly in diverse cancer types. In-depth understanding of cancer-specific synthetic lethal interactions will contribute to their application in cancer treatment, which will provide an important reference for exploring cancer-specific susceptibilities and further treatments.

Herein, toward the realization of the potential application of the concept of SL in cancer treatment, we aimed to predict and analyze candidate cancer-specific interactions through an integrative multi-omics analysis (Figure 1). Firstly, currently reported candidate genetic interactions were collected; an integrative analysis of multi-omics data analysis was performed to screen molecular features, mainly including DNA level [DNA mutation, copy number variation (CNV) and methylation] and mRNA expression level. Secondly, cancer-specific synthetic lethal interactions in 31 cancers were predicted using random forest (RF). Finally, we constructed a user-friendly and open-access database containing cancer-specific gene pairs and primary analysis. Our study may provide cancer-specific data sources and drug targets for further validation and clinical application in precision cancer therapy.

### Materials and methods

#### Data resource and data processing

In order to obtain cancer-specific synthetic lethal interactions, candidate genetic interactions were firstly collected to perform further analysis (Figure 1). A total of predicted 142,602 candidate synthetic lethal interactions were mainly obtained from DAISY (19) and MiSL (18) algorithms after removing redundancy. Further, 6,518 pairs of experimentally validated synthetic lethal interactions were collected according to published references, including 6,033 pairs from Lee et al. (30); 162 pairs validated in Hela, A549 and 293 T cell lines (31); 46 pairs from Syn-lethality database (21); 177 pairs from Srivasa et al. (32) and 100 reported gene pairs from published literature (Table S1). Simultaneously, another 2,467 pairs without SL in Hela, A549 and 293 T cell lines were also collected (31). Of these, 177 pairs were removed due to contradictory results in different analyses, 554 were removed due to repeated results and a total of 5,859 experimentally validated gene pairs and 2,395 validated pairs without SL were finally collected.

Multi-omics data, mainly including DNA mutation, CNV, methylation and mRNA expression data in 33 cancer types, were obtained from The Cancer Genome Atlas (TCGA) Web site using the TCGA/biolinks package (33). Genes were removed from further analysis if they were not detected in more than 10\% total samples according to mRNA expression level (reads per kilobase per million mapped reads, RPKM value), mutation, CNV and methylation (beta-value). Of these, \( n \) was defined as 7 according to a linear relationship of distributions of the median and average values to ensure that abnormal data had the least effect on the total data distribution. Furthermore, normalized normal data in 27 cancers from Genotype-Tissue Expression (GTEx) database (34, 35) were also downloaded to involve in differential expression analysis (Table S2).

#### Estimation of features from diverse molecular levels

For gene A:gene B pair, mutation coverage was estimated at mutation level (36) [Equation (1)]:

\[
\text{Score}_{MC} = \frac{A + B - C}{D}
\]

where \( A \) was the sample size with gene A mutation, \( B \) was the sample size with gene B mutation, \( C \) was the sample size with both genes mutated and \( D \) was the total sample size in a specific cancer type. At the mRNA level, dysregulated mRNA expression profiles were firstly analyzed using edgeR package (37), and only 31 cancer types were involved in differential expression analysis (mesothelioma and uveal melanoma were not involved in analysis due to lack of normal samples). The value of the mRNA expression feature was estimated using the following formula [Equation (2)]:

\[
\text{Score}_{mRNA} = \sqrt{\left(-\log_{10} p_{\text{adj}}\right)^2 + \left(\log_2 FC\right)^2}
\]

where fold change (FC) and \( p_{\text{adj}} \) (adjusted \( P \) value) were obtained from differential expression analysis using EdgeR.
Further, the average beta-value of each gene was calculated, and the value of methylation feature was estimated at the DNA methylation level [Equation (3)]:

\[
\text{Score}_{\text{methylation}} = \frac{\text{BetaValue}_A + \text{BetaValue}_B}{2}
\]

where BetaValue\(_A\) and BetaValue\(_B\) were beta-values of paired gene A and gene B, respectively. Finally, the feature was estimated at levels of gene amplification and deletion [Equation (4)]:

\[
\text{Score}_{\text{CNV}} = \frac{A + B}{C} \times \frac{1}{2}
\]

where \(A\) was the sample size of gene A with significant amplification (>1) or significant deletion (<−1), \(B\) was the sample size of gene B with significant amplification or deletion and \(C\) was the total sample size.

**Prediction of cancer-specific synthetic lethal interactions**

RF was used to predict cancer-specific synthetic lethal interactions using randomForest R package (38). The cancer-specific training set was firstly constructed based on the correlations of DNA mutation, mRNA expression and CNV levels. Specifically, if one gene was detected mutation, its partner would have a higher expression level and would be amplified more frequently or deleted less frequently harboring the mutation (18, 31). Then, based on the potential relationships of different molecular levels, experimentally validated gene pairs were defined as positive and negative samples. Moreover, some cancers were found with sample imbalance that might influence effective prediction, and a negative sampling strategy was used to improve recall (more than 70% after treatment in all cancer types). The model performance was estimated using a 10-fold cross-validation method, and the model was also evaluated using accuracy, recall and a receive operating characteristic curve to calculate the area under the curve (AUC). Then, for each cancer type, the whole data set was used to construct
the classifier. The primary predicted cancer-specific synthetic lethal interactions were collected by classifying the candidate interactions, and further filtering was performed based on strategies mentioned above to ensure the correctness.

Finally, according to predicted cancer-specific results, a user-friendly SLOAD database for data searching, browsing, downloading and analyzing was constructed.

Results

The overall predicted cancer-specific synthetic lethal interactions

The prediction performances using RF were better than our previous study using decision tree in cancers (Figure 2A). Both the accuracy and AUC values showed a significant difference between the two algorithms, indicating better prediction results using RF method (Figure 2B). Integrated feature of multi-omics data had a higher AUC value than the feature at the single molecular level (Figure 2C), despite different cancer types showing varied results. Of these, DNA mutation had a larger contribution to prediction accuracy, while methylation had less effect on the prediction of SL than other molecular levels. These results indicated that integrative analysis of multi-omics data was the best choice to predict cancer-specific synthetic lethal interactions, which provided more data reference for further discussing the potential molecular mechanisms associated with SL.

Herein, a total of 139,035 gene pairs were collected from 31 cancer types, containing 10,377 genes. Of these, most genes (75.78%) were detected in more than one interaction with other genes (Figure 2D). Genes with one interaction were the most popular (24.22%), followed by two interactions (10.97%), indicating that many genes were only found in rare synthetic lethal interactions, while some specific genes may have widespread interactions with other genes. For example, KRAS, PIK3CA and CSMD3 were found more than 1000 interactions. Indeed, KRAS, an oncogenic gene, has been validated by synthetic lethal interaction with other genes, and the determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells may contribute to revealing new therapeutic targeting strategies (39–41). These multiple interactions may implicate their important roles in tumorigenesis and further clinical application in cancer treatment based on the concept of SL.

Numbers of predicted gene pairs were different in 31 cancer types, and many synthetic lethal interactions were detected in multiple cancers, especially shared by 7–14 cancers (Figure 2E). Some gene pairs were shared by more than 20 cancers, such as TP53:ATR and CHEK2:TTN were detected in 29 cancer types. The genetic interactions among genes were complex (Figure 2F), especially for those pairs shared by multiple cancers. Some genes were involved in dynamic expression patterns across cancers, implicating the potential biological roles associated with specific cancers. These cancer-specific synthetic lethal interactions can provide candidate drug targets for precision treatment.

Web interface

SLOAD (http://www.tmliang.cn/SLOAD) provides a user-friendly web interface that allows users to query the database via multiple modules, mainly including ‘Search’, ‘Analysis’ and ‘Download’ (Figure 3A). Several search/selection boxes are designed to select a specific cancer type or all cancer types. The corresponding cancer-specific synthetic lethal interactions will be presented via inputting the interested gene symbol or paired genes. Each gene pair also indicates the shared number by diverse cancers (Figure 3B). For selected gene pair, further analysis can be presented, mainly including analysis of mutation, methylation, CNV and mRNA expression levels (Figure 3C), and all of these visible results are also obtained on the Analysis page by inputting the interested genes.

Users can comprehensively browse cancer-specific synthetic lethal interactions and corresponding analysis results of different molecular levels. On the ‘Download’ page, users can obtain free access to the main data sets of cancer-specific synthetic lethal interactions in 31 cancers. The ‘Help’ page provides the detailed information about SLOAD. Furthermore, SLOAD welcomes feedback via the email address presented on the ‘Contact us’ page.

Discussion and future directions

As a strategy in cancer therapy with increasing interests and potential applications, SL has been widely concerned in cancer treatment, especially for recent clinical success (8). Given the importance of SL, many studies aim to comprehensively obtain experimentally verified and computationally predicted candidate synthetic lethal interactions that can provide potential targets for anticancer drugs (18–21, 30, 32, 42–45), which can greatly promote the rapid development of cancer treatment based on the theory of SL (46). Although the concept of SL is an attractive therapeutic strategy, only PARPi has entered the clinic. One of the major hurdles is to identify clinically relevant and robust genetic interaction (47), and a critical challenge in personalized medicine is to identify mutation-specific therapies for a specific cancer type. Cancer-specific SL may be used as a promising cancer therapy, such as ATR and CHK1 inhibitors (48). It is urgent to provide cancer-specific synthetic lethal interactions, especially according to features of multi-omics data.

Herein, based on reported candidate synthetic lethal interactions, we aim to further predict cancer-specific SL via integrating analysis of multi-omics data, mainly including DNA mutation, CNV, methylation and mRNA expression levels. Although DNA mutation is the main contributor in the prediction of synthetic lethal interactions, other molecular levels also contribute to obtaining cancer-specific genetic interactions, and integrating analysis of multi-omics data could provide more information and potential correlations among different molecular levels. According to obtained molecular features, cancer-specific gene pairs are predicted using decision tree and RF, and the latter has the better prediction performance. Then, SLOAD database is constructed according to these predicted results using RF, and the primary analysis is also provided in the database. Taken together, SLOAD provides cancer-specific synthetic lethal interactions via integrating multi-omics analysis and prediction and also presents the primary analysis at the different molecular levels. These cancer-specific synthetic lethal interactions may contribute to discovering novel targets for targeted therapy and promoting further application in precision medicine.

In the future, we will continue to update SLOAD as follows: (i) we will perform an integrative analysis containing other molecular levels, especially the widely concerned...
Figure 2. Primary analysis of predicted cancer-specific synthetic lethal interactions.

(A) The distributions of AUC values based on different algorithms (decision tree and RF). (B) Significant difference of accuracy and AUC can be detected between different algorithms DT shows decision tree algorithm, and RF shows random forest algorithm. (C) The distributions of AUC values based on different feature selections across cancers. Feature selections mainly include feature of single molecular level and integrated features from multi-omics data. (D) The distribution of interacted numbers based on all the predicted synthetic lethal interactions, and the pie distribution is also presented. (E) The number distributions of synthetic lethal interactions shared by cancers. Many of these gene pairs are shared by multiple cancers, and several gene pairs shared by more than 28 cancers are highlighted. The below picture shows that diverse cancers are detected with different numbers of genetic interactions. (F) An example of an interaction network shows genetic interactions between genes. Each circle indicates a pie distribution of expression patterns in 31 cancers.
non-coding RNAs (ncRNAs). As a class of important regulators in RNA regulatory network, diverse ncRNAs, mainly including small negative regulators, microRNAs and their multiple isoforms, long ncRNAs and circular RNAs, have been focused because of the flexible roles during perturbing gene expression, particularly the cross-talks among various RNAs and subsequent biological pathways. The complex interaction of ncRNAs will enrich our understanding of SL. (ii) More algorithms will be used to improve prediction accuracy, and the relevant data are simultaneously updated. (iii) We will update additional online functions according to user feedback to ensure its value as a user-friendly cancer-specific synthetic lethal interactions database. We expect that SLOAD can contribute to research on cancer treatment based on the theory of SL in precision medicine.

Supplementary data

Supplementary data are available at Database Online.
Funding
This work was supported by the National Natural Science Foundation of China (nos. 62171236 and 61771251), the key project of social development in Jiangsu Province (no. BE2022799), the key projects of Natural Science Research in Universities of Jiangsu Province (22KJA180006), the Qinglan Project in Jiangsu Province, Sponsored by NUIPTSF (no. NY220041), the Open Research Fund of State Key Laboratory of Bioelectronics, Southeast University (SKLB2022-K03) and the Priority Academic Program Development of Jiangsu Higher Education Institution.

Conflict of interest
None declared.

Data availability
SLOAD (http://www.tmliang.cn/SLOAD/) is freely available to the public without registration or login requirements.

Abbreviation lists of involved cancers in TCGA
ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBCL, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LIHC, liver hepatocellular carcinoma; LGG, brain Lower grade glioma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.

References
1. Hartwell,L.H., Szankasi,P., Roberts,C.J. et al. (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science, 278, 1064–1068. 10.1126/science.278.5340.1064.
2. Zhang,B., Tang,C., Yao,Y. et al. (2021) The tumor therapy landscape of synthetic lethality. Nat. Commun., 12, 1275. 10.1038/s41467-021-21544-2.
3. Brody,L.C. (2005) Treating cancer by targeting a weakness. N. Engl. J. Med., 353, 949–950. 10.1056/NEJMcb052331.
4. Ma,H., Qi,G., Han,F. et al. (2022) HMGBl3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer. Cell Death Dis., 13, 263. 10.1038/s41419-022-04670-7.
5. Tewari,K.S., Eskander,R.N. and Monk,B.J. (2015) Development of olaparib for BRCA-deficient recurrent epithelial ovarian cancer. Clin. Cancer Res., 21, 3829–3835. 10.1158/1078-0432.CCR-15-0088.
6. Turk,A.A. and Wisinski,K.B. (2018) PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer, 124, 2498–2506. 10.1002/cncr.31307.
7. Lord,C.J. and Ashworth,A. (2017) PARP inhibitors: synthetic lethality in the clinic. Science, 355, 1152–1158. 10.1126/science.aam7344.
8. Lord,C.J., Tutt,A.N. and Ashworth,A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med., 66, 455–470. 10.1146/annurev-med-050915-022545.
9. Boss,D.S., Beijnen,J.H. and Schellens,J.H. (2010) Inducing synthetic lethality using PARP inhibitors. Curr. Clin. Pharmacol., 5, 192–195. 10.2174/157488410791498798.
10. Ashworth,A., Lord,C.J. and Reis-Filho,J.S. (2011) Genetic interactions in cancer progression and treatment. Cell, 145, 30–38. 10.1016/j.cell.2011.03.020.
11. Byrne,A.B., Weirauch,M.T., Wong,Y. et al. (2007) A global analysis of genetic interactions in Caenorhabditis elegans. J. Biol., 6, 8. 10.1186/jbionl58.
12. Costanzo,M., Baryshnikova,A., Bellay,J. et al. (2010) The genetic landscape of a cell. Science, 327, 425–431. 10.1126/science.1180823.
13. Tyypas,A., Nichols,R.J., Siegela,D.A. et al. (2008) High-throughput, quantitative analyses of genetic interactions in E. Coli. Nat. Methods, 5, 781–787. 10.1038/nmeth.1240.
14. Costanzo,M., VanderSluis,B., Koch,E.N. et al. (2016) A global genetic interaction network maps a wiring diagram of cellular function. Science, 353, aaf1420. 10.1126/science.aaf1420.
15. Bassik,M.C., Kampmann,M., Lehbk,R.J. et al. (2013) A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell, 152, 909–922. 10.1016/j.cell.2013.01.030.
16. Brough,R., Frankum,J.R., Costa-Cabral,S. et al. (2011) Searching for synthetic lethality in cancer. Curr. Opin. Genet. Dev., 21, 34–41. 10.1016/j.gded.2010.10.009.
17. Lauper,F., Fischer,B., Billmann,M. et al. (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat. Methods, 10, 427–431. 10.1038/nmeth.2436.
18. Sinha,S., Thomas,D., Chen,S. et al. (2017) Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nat. Commun., 8, 15580. 10.1038/ncomms15580.
19. Jerby-Aron,L., Pletzer,N., Waldman,Y.Y. et al. (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell, 158, 1199–1209. 10.1016/j.cell.2014.07.027.
20. Guo,J., Liu,H. and Zheng,J. (2016) SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. Nucleic Acids Res., 44, D1011–D1017. 10.1093/nar/gkv1108.
21. Li,X.J., Mishra,S.K., Wu,M. et al. (2014) Syn- lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies. Biomed. Res. Int., 2014, 196034. 10.1155/2014/196034.
22. Conde-Pueyo,N., Munteanu,A., Sole,R.V. et al. (2009) Human synthetic lethal inference as potential anti-cancer target gene detection. BMC Syst. Biol., 3, 116. 10.1186/1752-0509-3-116.
23. Folger,O., Jerby,L., Frezza,C. et al. (2011) Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol., 7, 501. 10.1038/msb.2011.35.
24. Frezza,C., Zheng,L., Folger,O. et al. (2011) Haem oxygogenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature, 477, 225–228. 10.1038/nature10363.
25. Lu,N., Kencshe,PR., Huyten,M.A. et al. (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. Nat. Commun., 4, 2124. 10.1038/ncomms3124.
26. Wang,S., Xu,F., Li,Y. et al. (2021) KG4SL: knowledge graph neural network for synthetic lethality prediction in human cancers. Bioinformatics, 37, i418–i425. 10.1093/bioinformatics/btab271.
27. Cai, R., Chen, X., Fang, Y. et al. (2020) Dual-dropout graph convolutional network for predicting synthetic lethality in human cancers. *Bioinformatics*, 36, 4458–4465. 10.1093/bioinformatics/btaa211.

28. Long, Y., Wu, M., Liu, Y. et al. (2021) Graph contextualized attention network for predicting synthetic lethality in human cancers. *Bioinformatics*, 37, 2342–2340. 10.1093/bioinformatics/btab110.

29. Wang, J., Wu, M., Huang, X. et al. (2022) SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery. *Database (Oxford)*, 2022, baac030. 10.1093/database/baac030.

30. Lee, J.S., Das, A., Jerby-Arnon, L., et al. (2018) Harnessing synthetic lethality to predict the response to cancer treatment. *Nat. Commun.*, 9, 2546. 10.1038/s41467-018-04647-1.

31. Shen, J.P., Zhao, D., Sasaki, R. et al. (2017) Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. *Nat. Methods*, 14, 573–576. 10.1038/nmeth.4225.

32. Srivastava, R., Shen, J.P., Yang, C.C. et al. (2016) A network of conserved synthetic lethal interactions for exploration of precision cancer therapy. *Mol. Cell*, 63, 514–525. 10.1016/j.molcel.2016.06.022.

33. Colaprico, A., Silva, T.C., Olsen, C. et al. (2016) TCGA-Biolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res.*, 44, e71. 10.1093/nar/gkv1507.

34. Carithers, L.J. and Moore, H.M. (2015) The genotype-tissue expression (GTEx) project. *Biopreserv Biobank*, 13, 307–308. 10.1089/bio.2015.29031.ham.

35. Consortium, G.T. (2013) The genotype-tissue expression (GTEx) project. *Nat. Genet.*, 45, 580–585. 10.1038/ng.2653.

36. Ye, H., Zhang, X., Chen, Y. et al. (2016) Ranking novel cancer driving synthetic lethal gene pairs using TCGA data. *Oncotarget*, 7, 55352–55367. 10.18632/oncotarget.10536.

37. Robinson, M.D., McCarthy, D.J. and Smyth, G.K. (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, 26, 139–140. 10.1093/bioinformatics/btp616.

38. Liaw, A. and Wiener, M. (2001) Classification and regression by randomForest. *Forest*, 2, 18–22.

39. Scholl, C., Frohling, S., Dunn, J.F. et al. (2009) Synthetic lethality interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. *Cell*, 137, 821–834. 10.1016/j.cell.2009.03.017.

40. Steckel, M., Molina-Arcas, M., Weigelt, B. et al. (2012) Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. *Cell Res.*, 22, 1227–1245. 10.1038/cr.2012.82.

41. Mao, C.Q., Xiong, M.H., Liu, Y. et al. (2014) Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. *Mol. Ther.*, 22, 964–973. 10.1038/mt.2014.18.

42. Whitehurst, A.W., Bodemann, B.O., Cardenas, J., et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. *Nature*, 446, 815–819. 10.1038/nature05697.

43. Bommi-Reddy, A., Almeiciga, I., Sawyer, J. et al. (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. *Proc. Natl. Acad. Sci. U.S.A.*, 105, 16484–16489. 10.1073/pnas.0806574105.

44. Luo, J., Emanuele, M.J., Li, D. et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell*, 137, 833–848. 10.1016/j.cell.2009.05.006.

45. Vizeacoumar, F.J., Arnold, R., Vizeacoumar, F.S. et al. (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol. Syst. Biol.*, 9, 696. 10.1038/msb.2013.54.

46. Wang, J., Zhang, Q., Han, J., et al. (2022) Computational methods, databases and tools for synthetic lethality prediction. *Brief. Bioinformatics*, 23, bbac106. 10.1093/bib/bbac106.

47. O’Neil, N.J., Bailey, M.L. and Hieter, P. (2017) Synthetic lethality and cancer. *Nat. Rev. Genet.*, 18, 613–623. 10.1038/nrg.2017.47.

48. Sanjiv, K., Hagenkort, A., Calderon-Montano, J.M. et al. (2016) Cancer-specific synthetic lethality between ATR and CHK1 kinase activities. *Cell Rep.*, 14, 298–309. 10.1016/j.celrep.2015.12.032.